Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer

Tumori

Volumn 92, Issue 4, 2006, Pages 290-294

  Rosati, Gerardo ^a,c   Cordio, Stefano ^b  

^a SAN CARLO HOSPITAL   (Italy)

^b S Luigi S Currò Hospital   (Italy)

^c NONE   (Italy)

Author keywords

Colorectal; Elderly; Irinotecan; Second line; Unresectable

Indexed keywords

FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER INCIDENCE; CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; MALE; MEDICAL LITERATURE; NAUSEA AND VOMITING; NEUTROPENIA; THROMBOCYTOPENIA; TOXICITY TESTING;

EID: 33749536950     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200405     Document Type: Article

References (19)

1. Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Thopam CA, Awad L, Jacques C, Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352: 1413-1418, 1998.
2. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 352: 1407-1412, 1998.
3. Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M, Rougier P: CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer, 31A: 1283-1287, 1995.
4. Pilot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Ghosh C, Kirschling RJ, Levitt R, Windschitl HE: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol, 15: 2910-2919, 1997.
5. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE Jr, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer, 85: 786-795, 1999.
6. Schoemaker NE, Kuppens IELM, Moiseyenko V, Glimelius B, Kjaer M, Starkhammer H, Richel DJ, Smaaland R, Bertelsen K, Poulsen JP, Voznyi E, Norum J, Fennelly D, Tveit KM, Garin A, Gruia G, Mourier A, Sibaud D, Lefebvre P, Beijnen JH, Schellens JH, ten Bokkel Huinink WW: A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer, 91: 1434-1441, 2004.
7. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol, 21: 807-814, 2003.
8. Hwang JJ, Eisenberg SG, Marshall JL: Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule. Oncology (Huntington), 17: 37-43, 2003.
9. Fentiman IS, Tirelli U, Monfardini S, Schneider M, Festen J, Cognetti F, Aapro MS: Cancer in the elderly: why so badly treated? Lancet, 28: 1020-1022, 1990.
10. Monfardini S, Yancik R: Cancer in the elderly: meeting the challenge of an aging population. J Natl Cancer Inst, 85: 532-538, 1993.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
12. Rougier P, Mitry E, Cunningham D, Roth A, Clavero-Fabri MC, Magherini E, Mery-Mignard D, Awad L, Douillard JY: Is age a prognostic factor of toxicity and efficacy in patients (pts) with metastatic colorectal cancer (MCRC) receiving irinotecan in combination with 5FU/folinic acid (FA). Proc Am Soc Clin Oncol, 22: 267, 2003.
13. Chau I, Norman AR, Cunningham D, Waters JS, Topham C, Middleton G, Hill M, Ross PJ, Katopodis R, Stewart G, Oates JR: Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer, 91: 1453-1458, 2004.
14. Rothenberg ML, Kuhn JG, Burris HA, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol, 11: 2194-2204, 1993.
15. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol, 13: 210-221, 1995.
16. Benavides M, Garcia-Alfonso P, Cobo M, Munoz-Martin A, Gil-Calle S, Carabantes F, Villar E, Graupera J, Balcells M, Perez-Manga G: Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. Med Oncol, 21: 255-262, 2004.
17. Karaoǧlu A, Yalcin S, Tekuzman G, Kars A, Celik I, Guler N, Ozisik Y, Turker A, Barista I, Gullu I: Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: efficacy and prognostic factors. Tumori, 89: 141-145, 2003.
18. Rougier P, Mitry E: Colorectal cancer chemotherapy: irinotecan. Semin Oncol, 27 (Suppl 10): 138-143, 2000.
19. Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 22: 1209-1214, 2004.